Rheumatoid Arthritis Epidemiology Summary
- Rheumatoid arthritis causes joint inflammation and pain. It happens when the immune system does not work properly and attacks the lining of the joints, called the synovium. The disease commonly affects the hands, knees or ankles, and usually the same joint on both sides of the body, such as both hands or both knees. But sometimes rheumatoid arthritis causes problems in other parts of the body as well, such as the eyes, heart and circulatory system and/or the lungs.
- In rheumatoid arthritis, an autoimmune disease, the immune system mistakenly attacks the synovium the lining of joints causing inflammation, thickening, pain, swelling, and reduced movement; while the exact cause is unclear, it is thought to involve genetic susceptibility triggered by environmental factors such as infections or stress.
- Rheumatoid arthritis is more common in women and about 75% of rheumatoid arthritis patients are women. Around 1 to 3% of women may get rheumatoid arthritis in their lifetime. The disease most often begins between the ages of 30 and 50. However, rheumatoid arthritis can start at any age.
- Typically, rheumatoid arthritis is diagnosed by a combination of patient's symptoms, results of doctor´s examination, assessment of risk factors, family history, a joint assessment by ultrasound sonography, and assessment of laboratory markers such as elevated levels of CRP and ESR in serum and detection of RA-specific autoantibodies.
- More than two thirds of rheumatoid arthritis patients have reported moderate to severe symptoms and having disease activity (DAS) score of 3.2 or above. And by this stage, most of the patients have joints that are experiencing swelling and pain and may have deformities, like malalignment, in some joints as a result of cartilage destruction.
Rheumatoid Arthritis Epidemiology Forecast in the United States
- 2025 Diagnosed Prevalent Cases of Rheumatoid Arthritis: ~4,871,000
- Rheumatoid Arthritis Growth Rate (2026–2036): XX CAGR
DelveInsight's ‘Rheumatoid Arthritis Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the glioma, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
|
Study Period
|
2022–2036
|
|
Historical Year
|
2022–2025
|
|
Forecast Period
|
2026–2036
|
|
Base Year
|
2026
|
|
Geographies Covered
|
ü North America : The US;
ü Europe: Germany, France, Italy, Spain and the UK;
ü Asia-Pacific: Japan
|
|
Rheumatoid Arthritis Epidemiology CAGR
(Study period/Forecast period)
|
XX (2025–2036)
|
|
Rheumatoid Arthritis Epidemiology Segmentation Analysis
|
Patient Burden Assesment
· Total Prevalent Cases of Rheumatoid Arthritis
· Total Diagnosed Prevalent Cases of Rheumatoid Arthritis
· Gender-specific Cases of Rheumatoid Arthritis
· Age-specific Cases of Rheumatoid Arthritis
· Severity-specific Cases of Rheumatoid Arthritis
|
Rheumatoid Arthritis Understanding and Diagnosis
Rheumatoid Arthritis Overview
Rheumatoid arthritis is a chronic systemic inflammatory autoimmune disease of unknown cause, typically presenting as bilateral, symmetric polyarthritis of the hands and feet, though any synovial joint and extra-articular organs such as the skin, heart, lungs, and eyes may be involved. It is believed to arise in genetically predisposed individuals (e.g., HLA-DR4/DR1 carriers) following environmental triggers like smoking or infection, leading to an autoimmune response. Although no single test is definitive, diagnosis relies on clinical evaluation and supportive findings such as inflammatory markers (ESR, CRP) and autoantibodies including rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP), with imaging (X-ray, ultrasound, MRI) used to assess joint damage and disease progression.
Further details are provided in the report...
Rheumatoid Arthritis Epidemiology
Key Findings from Rheumatoid Arthritis Epidemiological Analysis and Forecast
- As per Xu et al. (2021), in the US, approximately 1.3 million adults suffer from rheumatoid arthritis, representing 0.6% to 1% of the adult population.
- As per Stanciu et al. (2022), the estimated prevalence for rheumatoid arthritis in the adults is around 0.81%, with a higher prevalence for women (1.16%) than for men (0.44%) in the UK.
- According to the World Health Organization (2023), about 70% of people living with rheumatoid arthritis are women, and 55% are older than 55 years of age.
- As per Jinno et al. (2019) and Bergstra et al. (2018), the targeted therapies usage varies from 18% to 50% in Japan, which is similar to the usage of targeted therapies in the US.
- Rheumatoid arthritis mortality has decreased globally over the past three decades. Global age standardized prevalence rate have increased over the same period, and the number of cases is projected to continue to increase.
- While rheumatoid arthritis is a systemic autoimmune disease that affects multiple body systems, the joints of hands, wrists, feet, ankles, knees, shoulders and elbows are most often affected.
Scope of the Rheumatoid Arthritis Epidemiology Report
- The report covers a segment of an executive summary, a descriptive overview of rheumatoid arthritis, explaining its causes, signs and symptoms, and pathogenesis.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
Rheumatoid Arthritis Epidemiology Report Insights
- Rheumatoid Arthritis Patient Population Forecast
Rheumatoid Arthritis Epidemiology Report Key Strengths
- Epidemiology based (epi based) Bottom up Forecasting
- 11-year Forecast
- Patient Burden Trends (by geography)
Gain comprehensive Rheumatoid Arthritis market insights, epidemiology, emerging therapies, competitive intelligence, and forecast trends to identify growth opportunities through 2036.
FAQs
- What are the disease risks, burdens, and unmet needs of glioma? What will be the growth opportunities across the 7MM concerning the patient population with glioma?
- What is the historical and forecasted glioma patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy Rheumatoid Arthritis Epidemiology Report
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
- Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
1 Key Insights
2 Report Introduction
3 Executive Summary
4 Epidemiology Forecast Flow Methodology
5 Disease Background and Overview
5.1 Introduction
5.2 Stages of Rheumatoid Arthritis
5.3 Types of Rheumatoid Arthritis
5.3.1 Seropositive Rheumatoid Arthritis
5.3.2 Seronegative Rheumatoid Arthritis
5.4 Signs and Symptoms of Rheumatoid Arthritis
5.5 Risk Factors and Causes of Rheumatoid Arthritis
5.6 Complications of Rheumatoid Arthritis
5.7 Pathogenesis of Rheumatoid Arthritis
5.7.1 Disease Initiation
5.7.2 Triggers of Disease
5.7.3 Citrullination
5.7.4 Early and Established Rheumatoid Arthritis
5.7.5 Propagation of Disease
5.8 Diagnosis of Rheumatoid Arthritis
5.9 Screening of Rheumatoid Arthritis
6 Epidemiology and Patient Population of 7MM
6.1 Epidemiology Methodology
6.2 Key Findings
6.3 Assumptions and Rationale: 7MM
6.4 Epidemiology Scenario: 7MM
6.4.1 Total Prevalent Cases of Rheumatoid Arthritis in the 7MM
6.4.2 Total Diagnosed Prevalent Cases of Rheumatoid Arthritis in the 7MM
6.4.3 Gender-Specific Diagnosed Prevalent Cases of Rheumatoid Arthritis in the 7MM
6.4.4 Age-Specific Diagnosed Prevalent Cases of Rheumatoid Arthritis in the 7MM
6.4.5 Severity-Specific Diagnosed Prevalent Cases of Rheumatoid Arthritis in the7MM
6.5 The United States Epidemiology
6.5.1 Total Prevalent Cases of Rheumatoid Arthritis in the United States
6.5.2 Total Diagnosed Prevalent Cases of Rheumatoid Arthritis in the United States
6.5.3 Gender-Specific Diagnosed Prevalent Cases of Rheumatoid Arthritis in the United States
6.5.4 Age-Specific Diagnosed Prevalent Cases of Rheumatoid Arthritis in the United States
6.5.5 Severity-Specific Diagnosed Prevalent Cases of Rheumatoid Arthritis in the United States
6.6 EU4 and the UK Epidemiology
6.6.1 Total Prevalent Population of Rheumatoid Arthritis in EU4 and the UK
6.6.2 Total Diagnosed Prevalent Cases of Rheumatoid Arthritis in EU4 and the UK
6.6.3 Gender-Specific Diagnosed Prevalent Cases of Rheumatoid Arthritis in EU4 and the UK
6.6.4 Age-Specific Diagnosed Prevalent Cases of Rheumatoid Arthritis in EU4 and the UK
6.6.5 Severity-Specific Diagnosed Prevalent Cases of Rheumatoid Arthritis in EU4 and the UK
6.7 Japan Epidemiology
6.7.1 Total Prevalent Cases of Rheumatoid Arthritis in Japan
6.7.2 Total Diagnosed Prevalent Cases of Rheumatoid Arthritis in Japan
6.7.3 Gender-Specific Diagnosed Prevalent Cases of Rheumatoid Arthritis in Japan
6.7.4 Age-Specific Diagnosed Prevalent Cases of Rheumatoid Arthritis in Japan
6.7.5 Severity-Specific Diagnosed Prevalent Cases of Rheumatoid Arthritis in Japan
7 KOL Views
8 Appendix
8.1 Bibliography
8.2 Report Methodology
9 Delveinsight Capabilities
10 Disclaimer
11 About DelveInsight
The table of content is not exhaustive, will be provided in the full report..
List of Tables:
List of Tables
Table 1: Summary of Rheumatoid Arthritis Epidemiology (2022-2036)
Table 2: Total Prevalent Cases of Rheumatoid Arthritis in the 7MM (2022-2036)
Table 3: Total Diagnosed Prevalent Cases of Rheumatoid Arthritis in the 7MM (2022-2036)
Table 4: Gender-specific Prevalent Cases of Rheumatoid Arthritis in the 7MM (2022-2036)
Table 5: Age-specific Prevalent Cases of Rheumatoid Arthritis in the 7MM (2022-2036)
Table 6: Severity-specific Prevalent Cases of Rheumatoid Arthritis in the 7MM (2022-2036)
Table 7: Patients on targeted theRheumatoid Arthritispies of Rheumatoid Arthritis in the 7MM (2022-2036)
Table 8: Line-Wise Treated Cases of Rheumatoid Arthritis in the 7MM (2022-2036)
Table 9: Total Prevalent Cases of Rheumatoid Arthritis in the United States (2022-2036)
Table 10: Total Diagnosed Prevalent Cases of Rheumatoid Arthritis in the United States (2022-2036)
Table 11: Gender-specific Prevalent Cases of Rheumatoid Arthritis in the United States (2022-2036)
Table 12: Age-specific Prevalent Cases of Rheumatoid Arthritis in the United States (2022-2036)
Table 13: Severity-specific Prevalent Cases of Rheumatoid Arthritis in the United States (2022-2036)
Table 14: Patients on targeted theRheumatoid Arthritispies of Rheumatoid Arthritis in the United States (2022-2036)
Table 15: Line-Wise Treated Cases of Rheumatoid Arthritis in the United States (2022-2036)
Table 16: Total Prevalent Population of Rheumatoid Arthritis in EU4 and the UK (2022-2036)
Table 17: Total of Diagnosed Prevalent Cases of Rheumatoid Arthritis in EU4 and the UK (2022-2036)
Table 18: Gender-specific Prevalence of Rheumatoid Arthritis in EU4 and the UK (2022-2036)
Table 19: Age-specific Prevalence of Rheumatoid Arthritis in EU4 and the UK (2022-2036)
Table 20: Severity-specific Prevalent Cases of Rheumatoid Arthritis in EU4 and the UK (2022-2036)
Table 21: Patients on targeted theRheumatoid Arthritispies of Rheumatoid Arthritis in EU4 and the UK (2022-2036)
Table 22: Line-Wise Treated Cases of Rheumatoid Arthritis in EU4 and the UK (2022-2036)
Table 23: Total Prevalent Cases of Rheumatoid Arthritis in Japan (2022-2036)
Table 24: Total Diagnosed Prevalent Cases of Rheumatoid Arthritis in Japan (2022-2036)
Table 25: Gender-specific Prevalent Cases of Rheumatoid Arthritis in Japan (2022-2036)
Table 26: Age-specific Prevalent Cases of Rheumatoid Arthritis in Japan (2022-2036)
Table 27: Severity-specific Prevalent Cases of Rheumatoid Arthritis in Japan (2022-2036)
Table 28: Patients on targeted theRheumatoid Arthritispies of Rheumatoid Arthritis in Japan (2022-2036)
Table 29: Line-Wise Treated Cases of Rheumatoid Arthritis in Japan (2022-2036)
List of Figures:
List of Figures
Figure 1: Rheumatoid Arthritis Distressed Area
Figure 2: Bone joint differentiation of normal and Rheumatoid Arthritis
Figure 3: Development and progression of Rheumatoid Arthritis
Figure 4: Sign and Symptoms of Rheumatoid Arthritis
Figure 5: Associations and links for Rheumatoid Arthritis
Figure 6: Initiation and Progression of Rheumatoid Arthritis
Figure 7: Clinical manifestations of Rheumatoid Arthritis
Figure 8: Antinuclear Antibody Test
Figure 9: Clinical Diagnosis of Rheumatoid Arthritis
Figure 10: Diagnostic criteria for Rheumatoid Arthritis
Figure 11: Screening for Rheumatoid Arthritis
Figure 12: Total Prevalent Cases of Rheumatoid Arthritis in the 7MM (2022-2036)
Figure 13: Total Diagnosed Prevalent Cases of Rheumatoid Arthritis in the 7MM (2022-2036)
Figure 14: Gender-specific Prevalent Cases of Rheumatoid Arthritis in the 7MM (2022-2036)
Figure 15: Age-specific Prevalent Cases of Rheumatoid Arthritis in the 7MM (2022-2036)
Figure 16: Severity-specific Prevalent Cases of Rheumatoid Arthritis in the 7MM (2022-2036)
Figure 17: Patients on targeted theRheumatoid Arthritispies of Rheumatoid Arthritis in the 7MM (2022-2036)
Figure 18: Line-Wise Treated Cases of Rheumatoid Arthritis in the 7MM (2022-2036)
Figure 19: Total Prevalent Cases of Rheumatoid Arthritis in the United States (2022-2036)
Figure 20: Total Diagnosed Prevalent Cases of Rheumatoid Arthritis in the United States (2022-2036)
Figure 21: Gender-specific Prevalent Cases of Rheumatoid Arthritis in the United States (2022-2036)
Figure 22: Age-specific Prevalent Cases of Rheumatoid Arthritis in the United States (2022-2036)
Figure 23: Severity-specific Prevalent Cases of Rheumatoid Arthritis in the United States (2022-2036)
Figure 24: Patients on targeted theRheumatoid Arthritispies of Rheumatoid Arthritis in the United States (2022-2036)
Figure 25: Line-Wise Treated Cases of Rheumatoid Arthritis in the United States (2022-2036)
Figure 26: Total Prevalent Cases of Rheumatoid Arthritis in EU4 and the UK (2022-2036)
Figure 27: Total Diagnosed Prevalent Cases of Rheumatoid Arthritis in EU4 and the UK (2022-2036)
Figure 28: Gender-specific Prevalent Cases of Rheumatoid Arthritis in EU4 and the UK (2022-2036)
Figure 29: Age-specific Prevalent Cases of Rheumatoid Arthritis in EU4 and the UK (2022-2036)
Figure 30: Severity-specific Prevalent Cases of Rheumatoid Arthritis in EU4 and the UK (2022-2036)
Figure 31: Patients on targeted theRheumatoid Arthritispies of Rheumatoid Arthritis in EU4 and the UK (2022-2036)
Figure 32: Line-Wise Treated Cases of Rheumatoid Arthritis in EU4 and the UK (2022-2036)
Figure 33: Total Prevalent Cases of Rheumatoid Arthritis in Japan (2022-2036)
Figure 34: Total Diagnosed Prevalent Cases of Rheumatoid Arthritis in Japan (2022-2036)
Figure 35: Gender-specific Prevalent Cases of Rheumatoid Arthritis in Japan (2022-2036)
Figure 36: Age-specific Prevalent Cases of Rheumatoid Arthritis in Japan (2022-2036)
Figure 37: Severity-specific Prevalent Cases of Rheumatoid Arthritis in Japan (2022-2036)
Figure 38: Patients on targeted theRheumatoid Arthritispies of Rheumatoid Arthritis in Japan (2022-2036)
Figure 39: Line-Wise Treated Cases of Rheumatoid Arthritis in Japan (2022-2036)
-pipeline.png&w=256&q=75)
